ALIM - アリメラ・サイエンシ―ズ （Alimera Sciences Inc.） アリメラ・サイエンシ―ズALIMのチャート
ALIMの企業情報
| symbol | ALIM |
|---|---|
| 会社名 | Alimera Sciences Inc. （アリメラ・サイエンシ―ズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 アリメラ・サイエンシーズ(Alimera Sciences Inc.)は処方眼科医薬品の研究・開発・商業化を専門に扱うバイオ医薬品企業。同社は眼底や網膜に影響を与える疾患を中心に取り扱う。同社の製品候補「ILUVIEN」は非外科的治療手順であり、25ゲージ針付きのデバイスを採用し、傷のセルフシールを可能にする。また、「ILUVIEN」はドライ型加齢黄斑変性症（AMD）、ウェット型AMD及び網膜静脈閉塞症（RVO）を治療するために３つの第２相臨床試験で研究されている。「ILUVIEN」は硝子体内インプラントであり、非独占の副腎皮質ステロイドであるフルオシノロンアセトニド（FAc）の持続的なサブマイクログラムレベルを提供することにより、糖尿病性黄斑浮腫（DME）に関連する視力障害の治療で最大36ヶ月の治療効果を提供する。 アリメラ・サイエンシ―ズは米国のバイオ医薬品メ―カ―。眼科薬の研究、開発、商業化に従事。主に、眼球の裏側や網膜に影響を及ぼす疾患に焦点を当てている。慢性糖尿病性黄斑浮腫に関連した視力障害治療薬「イルビエン」は、英国、オ―ストリア、ポルトガル、フランス、ドイツ、スペインで販売承認を受けている。本社はジョ―ジア州。 Alimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging populations. |
| 本社所在地 | 6120 Windward Parkway Suite 290 Alpharetta GA 30005 USA |
| 代表者氏名 | Richard S. Eiswirth リチャードエスワース |
| 代表者役職名 | President Chief Financial Officer |
| 電話番号 | +1 678-990-5740 |
| 設立年月日 | 37773 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2010年 |
| 従業員数 | 126人 |
| url | www.alimerasciences.com |
| nasdaq_url | https://www.nasdaq.com/symbol/alim |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -14.46000 |
| 終値（lastsale） | 0.931 |
| 時価総額（marketcap） | 65205760.641 |
| 時価総額 | 時価総額（百万ドル） 66.07424 |
| 売上高 | 売上高（百万ドル） 39.64500 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 156.19224 |
| 当期純利益 | 当期純利益（百万ドル） -24.19300 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Alimera Sciences Inc revenues increased 22% to $20.7M. Net loss increased 23% to $11.7M. Revenues reflect United States segment increase of 20% to $15M International segment increase of 28% to $5.7M. Higher net loss reflects United States segment loss increase of 21% to $2.7M International segment loss increase of 27% to $1.2M. |
ALIMのテクニカル分析
ALIMのニュース
Alimera Sciences will move its headquarters into the latest phase of a 135-acre Alpharetta project 2021/06/02 12:03:07 BusinessMag
Alimera maintains its headquarters in a 2-story building at 6120 Windward Parkway that was developed over 20 years ago.
Alimera Sciences, Inc. to Present at the Summer Solstice Best Ideas from the Buy Side Conference on June 2, 2021 2021/05/27 12:15:00 GlobeNewswire
ATLANTA, May 27, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that management has been invited to present at the Summer Solstice - Best Ideas from the Buy Side Conference, which is being held virtually on June 1 June 4, 2021.
Advanced Ophthalmology Technologies Market to Witness Growth Acceleration by Top Key Players Johnson & Johnson, Novartis, Alimera Sciences, Teva Pharmaceutical, Bausch + Lomb, CooperVision 2021/05/19 06:49:23 Jumbo News
Global Advanced Ophthalmology Technologies Market size, share and CAGR Analysis 2021-2027 Advanced Ophthalmology Technologies Market report performs comprehensive Analysis about Global Market and tells about the market status in the forecast period. The report recognizes and analyses the growing trends along with major drivers, restraints, challenges and opportunities in the Advanced Ophthalmology Technologies industry. The []
2021 Global Retinal Disorders Drugs Market Is Booming by Leading Players| ALLERGAN, AbbVie, Alimera Sciences, Janssen Biotech, Swedish Orphan Biovitrum 2021/05/13 03:57:54 Jumbo News
May13,2021 (Reports and Markets) Retinal Disorders Drugs Market is growing at a High CAGR during the forecast period 2021-2027. This report studies the Retinal Disorders Drugs market with many aspects of the industry like the market size, market status, market trends and forecast, the report also provides brief information of the competitors and the specific []
Alimera Sciences Inc. Shares Close the Week 47.9% Higher - Weekly Wrap 2021/03/12 22:30:00 Kwhen Finance
Alimera Sciences Inc. shares closed this week 47.9% higher than it did at the end of last week. The stock is currently up 164.0% year-to-date, up 156.1% over the past 12 months, and down 56.1% over the past five years. This week, the Dow Jones Industrial Average rose 4.1%, and the S&P 500 rose 2.7%. Trading Activity Shares traded as high as $11.50 and as low as $7.44 this week.Shares closed 3% below its 52-week high and 3e+2% above its 52-week low.Trading volume this week was 20.4% lower than the 10-day average and 13.6% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price beats the S&P 500 Index this week, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, beats it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 663.5% The company's stock price performance over the past 12 months beats the peer average by 274.1%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Alimera Sciences will move its headquarters into the latest phase of a 135-acre Alpharetta project 2021/06/02 12:03:07 BusinessMag
Alimera maintains its headquarters in a 2-story building at 6120 Windward Parkway that was developed over 20 years ago.
Alimera Sciences, Inc. to Present at the Summer Solstice Best Ideas from the Buy Side Conference on June 2, 2021 2021/05/27 12:15:00 GlobeNewswire
ATLANTA, May 27, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that management has been invited to present at the Summer Solstice - Best Ideas from the Buy Side Conference, which is being held virtually on June 1 June 4, 2021.
Advanced Ophthalmology Technologies Market to Witness Growth Acceleration by Top Key Players Johnson & Johnson, Novartis, Alimera Sciences, Teva Pharmaceutical, Bausch + Lomb, CooperVision 2021/05/19 06:49:23 Jumbo News
Global Advanced Ophthalmology Technologies Market size, share and CAGR Analysis 2021-2027 Advanced Ophthalmology Technologies Market report performs comprehensive Analysis about Global Market and tells about the market status in the forecast period. The report recognizes and analyses the growing trends along with major drivers, restraints, challenges and opportunities in the Advanced Ophthalmology Technologies industry. The []
2021 Global Retinal Disorders Drugs Market Is Booming by Leading Players| ALLERGAN, AbbVie, Alimera Sciences, Janssen Biotech, Swedish Orphan Biovitrum 2021/05/13 03:57:54 Jumbo News
May13,2021 (Reports and Markets) Retinal Disorders Drugs Market is growing at a High CAGR during the forecast period 2021-2027. This report studies the Retinal Disorders Drugs market with many aspects of the industry like the market size, market status, market trends and forecast, the report also provides brief information of the competitors and the specific []
Alimera Sciences Inc. Shares Close the Week 47.9% Higher - Weekly Wrap 2021/03/12 22:30:00 Kwhen Finance
Alimera Sciences Inc. shares closed this week 47.9% higher than it did at the end of last week. The stock is currently up 164.0% year-to-date, up 156.1% over the past 12 months, and down 56.1% over the past five years. This week, the Dow Jones Industrial Average rose 4.1%, and the S&P 500 rose 2.7%. Trading Activity Shares traded as high as $11.50 and as low as $7.44 this week.Shares closed 3% below its 52-week high and 3e+2% above its 52-week low.Trading volume this week was 20.4% lower than the 10-day average and 13.6% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price beats the S&P 500 Index this week, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, beats it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 663.5% The company's stock price performance over the past 12 months beats the peer average by 274.1%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Alimera Science's Innovative Treatment for Diabetic Macular Edema Vision Loss Lasts for up to 3 Years 2021/04/26 14:51:33 Benzinga
Intravitreal Implant Provides a Daily Microdose Release to Reduce Disease Recurrence Amid required stay-at-home orders, many have paused or canceled doctor’s appointments over the past 12 months. Recent studies show some of the troubling effects of patients missing out on treatments for vision loss. Alimera Sciences believes it has a solution. A Daily Microdose Recently, the Cleveland Clinic published a paper, “The Effect of Delay in Care Among Patients Requiring Intravitreal Injections,” regarding the results of patients missing their prescribed vision loss treatments due to the COVID pandemic. This 1,041-patient retrospective analysis examined the effect of a delay in care on the visual acuity of patients requiring intravitreal injections. The authors looked at patients with retina disease who had received an intravitreal injection in the 12-week period prior to March 14, 2020 (start of the lockdowns). Patients in the study were divided into 3 groups: those that completed their scheduled visit during the time period from March 14 to May 4, 2020; those that canceled their scheduled visit during that period; and no-shows.
Alimera, Ocumension Ink Licensing Pact For Fluocinolone Acetonide Eye Implant In China 2021/04/14 14:34:55 Benzinga
Ocumension Therapeutics has inked an exclusive license agreement for Alimera Sciences Inc's (NASDAQ: ALIM ) 0.19mg fluocinolone acetonide intravitreal implant. The license grants Ocumension the rights to develop and commercialize the implant to treat diabetic macular edema and other retina diseases (excluding uveitis) in the Greater China territory and other … Full story available on Benzinga.com
The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts 2021/02/11 12:26:22 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 11) 10X Genomics Inc (NASDAQ: TXG ) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Abbott Laboratories (NYSE: ABT ) Acasti Pharma Inc (NASDAQ: ACST ) (reacted to its quarterly results) Advaxis, Inc. (NASDAQ: ADXS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alimera Sciences Inc (NASDAQ: ALIM ) Alkermes Plc (NASDAQ: ALKS ) Allakos Inc (NASDAQ: ALLK ) Anchiano Therapeutics Ltd – ADR (NASDAQ: ANCN AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Apyx Medical Corp (NASDAQ: APYX ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Artelo Biosciences Inc (NASDAQ: ARTL ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) AtriCure Inc. (NASDAQ: ATRC ) Avanos Medical Inc (NYSE: AVNS ) Beigene Ltd (NASDAQ: BGNE ) Bio-Path Holdings Inc (NASDAQ: BPTH ) (announced receipt of third patent related to manufacture of platform technology) Bolt Biotherapeutics Inc (NASDAQ: BOLT ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cancer Genetics Inc (NASDAQ: CGIX ) (reacted to an update to merger terms with StemoniX) Cara Therapeutics Inc (NASDAQ: CARA ) Celcuity Inc (NASDAQ: CELC ) Cellular Biomedicine Group Inc (NASDAQ: CBMG ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Clearside Biomedical Inc (NASDAQ: CLSD ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) Edap Tms SA (NASDAQ: EDAP ) Evogene Ltd (NASDAQ: EVGN ) Eyenovia Inc (NASDAQ: EYEN ) G1 Therapeutics Inc (NASDAQ: GTHX ) Gamida Cell Ltd (NASDAQ: GMDA ) ( reacted to a positive late-stags readout) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) Glaukos Corp (NYSE: GKOS ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Ideaya Biosciences Inc (NASDAQ: IDYA ) Illumina, Inc.
The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa 2021/01/22 12:22:33 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 21) Acasti Pharma Inc (NASDAQ: ACST ) Alimera Sciences Inc (NASDAQ: ALIM ) argenx SE – ADR (NASDAQ: ARGX ) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) AzurRx BioPharma Inc (NASDAQ: AZRX ) Chimerix Inc (NASDAQ: CMRX ) Edap Tms SA (NASDAQ: EDAP ) Eli Lilly And Co (NYSE: LLY ) (announced positive results for its COVID-19 antibody treatment) ESSA Pharma Inc (NASDAQ: EPIX ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Inari Medical Inc (NASDAQ: NARI ) INmune Bio Inc (NASDAQ: INMB ) ( INSM ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Inventiva ADR Representing Ord Shs (NASDAQ: IVA ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Krystal Biotech Inc (NASDAQ: KRYS ) Laboratory Corp. of America Holdings (NYSE: LH ) Merus NV (NASDAQ: MRUS ) Neuronetics Inc (NASDAQ: STIM ) OncoSec Medical Inc (NASDAQ: ONCS ) (announced common stock offering) PRA Health Sciences Inc (NASDAQ: PRAH ) Precision BioSciences Inc (NASDAQ: DTIL ) Profound Medical Corp (NASDAQ: PROF ) Renalytix AI PLC (NASDAQ: RNLX ) Rhythm Pharmaceuticals Inc (NASDAQ: RYTM ) Seelos Therapeutics Inc (NASDAQ: SEEL ) Surface Oncology Inc (NASDAQ: SURF ) Syneos Health Inc (NASDAQ: SYNH ) Synlogic Inc (NASDAQ: SYBX ) Twist Bioscience Corp (NASDAQ: TWST ) Vericel Corp (NASDAQ: VCEL ) Xencor Inc (NASDAQ: XNCR ) Down In The Dumps None of the biotech/medical device/diagnostic stocks hit 52-week highs in the session.